The main objective of the AntiMal Integrated Project is to generate novel antimalarial drugs with potential for use in humans, specifically to progress candidate molecules to the “first time into humans” stage of drug development. To achieve this goal, leading groups of malaria researchers from Europe and Africa with expertise in malaria biology, chemotherapy and drug development have come together to exploit new scientific and political opportunities to secure the development of a portfolio of viable antimalarial drugs. Ultimately these new chemical entities will be commercially attractive to industrial partners and through the generation of Public Private Partnerships (PPP’s), will result in affordable new antimalarial drugs registered to internationally recognised standards. There are 37 partners working in 15 countries, 5 of which are in Africa and 10 in Europe.
AntiMal Fight – The Buzzing Killers
The main objective of the AntiMal Integrated Project is to generate novel antimalarial drugs with potential for use in humans, specifically to progress candidate molecules to the “first time into humans” stage of drug development. To achieve this goal, leading groups of malaria researchers from Europe and Africa with expertise in malaria biology, chemotherapy and drug development have come together to exploit new scientific and political opportunities to secure the development of a portfolio of viable antimalarial drugs. Ultimately these new chemical entities will be commercially attractive to industrial partners and through the generation of Public Private Partnerships (PPP’s), will result in affordable new antimalarial drugs registered to internationally recognised standards. There are 37 partners working in 15 countries, 5 of which are in Africa and 10 in Europe.
